A
Aytu BioPharma, Inc. (AYTU)
NCM – Real Time Price. Currency in USD
2.60
-0.07 (-2.80%)
At close: Mar 27, 2026, 4:00 PM EDT
2.55
-0.05 (-1.92%)
After-hours: Mar 27, 2026, 4:26 PM EDT

NCM – Real Time Price. Currency in USD
2.60
-0.07 (-2.80%)
At close: Mar 27, 2026, 4:00 PM EDT
2.55
-0.05 (-1.92%)
After-hours: Mar 27, 2026, 4:26 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 1.16 | 2.52 | 7.0 | |
| Quick ratio | 1.03 | 1.78 | 7.0 | |
| Debt to Equity | 1.56 | -0.80 | 4.0 | |
| Debt to Assets | 0.18 | 0.73 | 8.0 | |
| Interest coverage | -3.52 | -13.90 | 1.0 | |
| Weighted average score | 5.4 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 97M | 107M | 65M | 66M | 63M |
| Gross Profit | 46M | 62M | 45M | 42M | 39M |
| Operating Income | -38M | -12M | 565K | 3M | -413K |
| Net Income | -109M | -17M | -16M | -14M | -24M |
| EBITDA | -28M | -4M | 7M | 8M | 4M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | -29.26 | -385 | 1.0 |
| Next quarter | -0.74 | 90.78 | 5.5 |
| Current year | -14.05 | 45.13 | 5.5 |
| Next year | 42.65 | 81.45 | 10 |
| Weighted average score | 5.5 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 9.19 | -638.62 | -1212.49 | 691.91 | 4.5 |
| Y/Y | -6.5 | -1443.14 | -274.99 | 26.18 | 3.3 |
| 3y average | -8.78 | 35.27 | 52.73 | 40.97 | 7.8 |
| 5y average | 31.69 | -61.73 | 26.89 | 24.08 | 7.8 |
| Weighted average score | 5.9 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $30.0M significantly exceed its total debt $22.1M, ensuring strong financial flexibility
Total current assets $76.2M exceed Total current liabilities $65.6M, highlighting excellent liquidity
Debt-to-equity ratio (1.6) far exceeds the industry average, reflecting over-leverage
Interest coverage ratio (-3.5x) is dangerously low, suggesting debt repayment risks
The company generates positive free cash flow $3.7M, supporting its financial health